Retinoblastoma protein-interacting zinc finger 1 (RIZ1) participates in RANKL-induced osteoclast formation via regulation of NFATc1 expression

Immunology Letters

Volumn 131, Issue 2, 2010, Pages 166-169

  Noman, Abu Shadat Mohammod ^a   Koide, Naoki ^a   Iftakhar E Khuda, Imtiaz ^a   Dagvadorj, Jargalsaikhan ^a   Tumurkhuu, Gantsetseg ^a   Naiki, Yoshikazu ^a   Komatsu, Takayuki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

NFATc1; Osteoclastogenesis; RANKL; RAW 264.7; RIZ1

Indexed keywords

NUCLEAR FACTOR OF ACTIVATED T CELL 1; OSTEOCLAST DIFFERENTIATION FACTOR; RETINOBLASTOMA PROTEIN INTERACTING ZINC FINGER 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ACID PHOSPHATASE; DIFFERENTIATION ANTIGEN; HISTONE LYSINE METHYLTRANSFERASE; ISOENZYME; PRDM2 PROTEIN, MOUSE; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSFECTION; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ACID PHOSPHATASE; ANIMALS; ANTIGENS, DIFFERENTIATION; BONE RESORPTION; CELL LINE; GENE EXPRESSION REGULATION; HISTONE-LYSINE N-METHYLTRANSFERASE; ISOENZYMES; MACROPHAGES; MICE; NEOPLASMS; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77953695770     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.04.006     Document Type: Article

References (32)

1. Du Y., Carling T., Fang W., Piao Z., Sheu J.C., Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res 2001, 61:8094-8099.
2. Huang S., Shao G., Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem 1998, 273:15933-15939.
3. Carling T., Kim K.C., Yang X.H., Gu J., Zhang X.K., Huang S. A histone methyltransferase is required for maximal response to female sex hormones. Mol Cell Biol 2004, 24:7032-7042.
4. Abbondanza C., de Nigris F., De Rosa C., Rossiello R., Puca G.A., Napoli C. Silencing of YY1 downregulates RIZ1 promoter in human osteosarcoma. Oncol Res 2008, 17:33-41.
5. He L., Yu J.X., Liu L., Buyse I.M., Wang M.S., Yang Q.C., et al. RIZ1, but not the alternative RIZ2 product of the same gene, is under expressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 1998, 58:4238-4244.
6. Coleman R.E. Management of bone metastases. Oncologist 2000, 5:463-470.
7. Lee N.K., Choi H.K., Yoo H.J., Shin J., Lee S.Y. RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis. Cell Signal 2008, 20:2302-2308.
8. Lee S.W., Kwak H.B., Lee H.C., Lee S.K., Kim H.H., Lee Z.H. The anti-proliferative gene TIS21 is involved in osteoclast differentiation. J Biochem Mol Biol 2002, 35:609-614.
9. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
10. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
11. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
12. Lee Z.H., Kim H.H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003, 305:211-214.
13. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
14. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638-649.
15. Wati S., Li P., Burrell C.J., Carr J.M. Dengue virus (DV) replication in monocyte-derived macrophages is not affected by tumor necrosis factor alpha (TNF-α), and DV infection induces altered responsiveness to TNF-α stimulation. J Virol 2007, 81:10161-10171.
16. Noman A.S., Koide N., Khuda I.I., Dagvadorj J., Tumurkhuu G., Naiki Y., et al. Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation. Biochem Biophys Res Commun 2008, 374:683-687.
17. Hassan F., Islam S., Tumurkhuu G., Naiki Y., Koide N., Mori I., et al. Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer 2006, 6:281.
18. Islam S., Hassan F., Tumurkhuu G., Dagvadorj J., Koide N., Naiki Y., et al. Receptor activator of NF-kappaB ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony stimulating factor. Microbiol Immunol 2008, 52:585-590.
19. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
20. Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999, 4:353-362.
21. Cole A.A., Walters L.M. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold-embedding in plastic. J Histochem Cytochem 1987, 35:203-206.
22. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997, 11:3482-3496.
23. David J.P., Sabapathy K., Hoffmann O., Idarraga M.H., Wagner E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002, 115:4317-4325.
24. Sugatani T., Hruska K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005, 280:3583-3589.
25. Jiang G., Liu L., Buyse I.M., Simon D., Huang S. Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1. Int J Cancer 1999, 83:541-546.
26. Chadwick R.B., Jiang G.L., Bennington G.A., Yuan B., Johnson C.K., Stevens M.W., et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci USA 2000, 97:2662-2667.
27. Sasaki O., Meguro K., Tohmiya Y., Funato T., Shibahara S., Sasaki T. Altered expression of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukaemia. Br J Haematol 2002, 119:940-948.
28. Poetsch M., Dittberner T., Woenckhaus C. Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. Oncogene 2002, 21:3038-3042.
29. Dougall W.C. RANKL signaling in bone physiology and cancer. Curr Opin Support Palliat Care 2007, 1:317-322.
30. Avnet S., Longhi A., Salerno M., Halleen J.M., Perut F., Granchi D., et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 2008, 33:1231-1238.
31. Noman AS, Koide N, Hassan F, Khuda II, Dagvadorj J, Tumurkhuu G, et al. Retinoblastoma protein-interacting zinc finger 1, a tumor suppressor, augments lipopolysaccharide-induced proinflammatory cytokine production via enhancing nuclear factor-κB activation. Cell Immunol; submitted for publication.
32. Islam S., Hassan F., Tumurkhuu G., Dagvadorj J., Koide N., Naiki Y., et al. Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 2007, 360:346-351.